Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

10 participants

Study Classification

OBSERVATIONAL

Study Start Date

2028-01-31

Study Completion Date

2036-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This prospective observational study evaluates the safety profile and patient-reported outcomes associated with MUSE (Multilineage-differentiating Stress-Enduring) stem cell therapy in individuals aged 6 to 75 with chronic traumatic brain injury (TBI). Participants independently elect to receive MUSE cell treatment through international clinical programs, and this study aims to capture real-world evidence on the potential therapeutic effects and risks of this emerging regenerative approach.

The study does not administer any intervention. Instead, it follows participants who have received, or plan to receive, MUSE cell infusions outside the United States. Over a 12-month follow-up period, data will be collected on neurological functioning, quality of life, activities of daily living, and any reported adverse events or complications. Information will be gathered through remote interviews, structured digital surveys, and review of medical documentation when available.

This research is sponsored by Healing Hope International and is intended to contribute to the ethical and responsible advancement of novel cell-based therapies by generating real-world evidence that may guide future clinical trial development and inform patient care practices.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of the Effects of Early Proprioceptive Stimulations in Patients With Severe Traumatic Brain Injury

NCT05094999

Traumatic Brain Injuries

UNKNOWN NA

Noninvasive Brain Stimulation on Memory in Individuals With Mild Cognitive Impairment and History of Brain Injury

NCT04504630

Amnestic Mild Cognitive Impairment Traumatic Brain Injury Mild Traumatic Brain Injury

COMPLETED NA

Non-invasive Brain Stimulation for Cognitive and Motor Dysfunction in Dementia

NCT05661084

Dementia Memory Loss Alzheimer Disease +2 more

RECRUITING NA

Acute Intermittent Hypoxia in Traumatic Brain Injury

NCT04890639

Brain Injuries, Traumatic

RECRUITING NA

Strategy Based Technique to Enhance Memory (STEM) for Improving New Learning and Memory (NLM) in Moderate to Severe TBI

NCT04054596

Traumatic Brain Injury Cognitive Impairment

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational study is designed to systematically evaluate the safety, tolerability, and potential neurological outcomes associated with MUSE (Multilineage-differentiating Stress-Enduring) stem cell therapy in individuals with chronic traumatic brain injury (TBI) who independently obtain treatment through international clinical programs.

MUSE cells are a distinct subpopulation of mesenchymal stem cells characterized by stress resilience, spontaneous triploblastic differentiation, and the capacity to home to sites of tissue injury. Preclinical research suggests that MUSE cells may contribute to neuroregeneration through differentiation into neural and glial lineages, modulation of inflammatory pathways, and repair of damaged central nervous system structures. While early findings are promising, clinical evidence remains limited, highlighting the need for structured real-world data.

This study does not randomize participants or administer any treatment. Instead, it functions as a registry-style, real-world evidence platform following individuals who have elected to receive MUSE cell therapy at licensed facilities outside the United States. Collected data will include baseline demographics, TBI history, details of the stem cell procedure (such as cell source, administered dose, and route of delivery), and longitudinal follow-up over 12 months.

Primary domains of interest include:

Neurological function, assessed with validated clinical instruments (e.g., Glasgow Outcome Scale-Extended).

Quality of life, measured using standardized patient-reported outcome tools (e.g., PROMIS-29, EQ-5D).

Functional abilities and activities of daily living, to assess practical day-to-day impact.

Safety and tolerability, including documentation of adverse events, patient-reported symptoms, and any medical complications.

Data will be obtained through remote telemedicine visits, structured digital surveys, and review of available medical records. This study does not collect biospecimens and does not involve the administration of any investigational product.

The overarching objective is to generate high-quality real-world evidence regarding the use of MUSE stem cells in chronic TBI, supporting the scientific foundation needed for future controlled clinical trials and potential compassionate use pathways. The study is conducted by Healing Hope International, a nonprofit organization dedicated to advancing ethical access and research in regenerative medicine.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Traumatic Brain Injury Traumatic Brain Injury (TBI) Patients Traumatic Brain Injury (TBI); Concussion, Initial Encounter Traumatic Brain Injury (TBI); Concussion, Subsequent Encounter Traumatic Brain Injury With Brief Loss of Consciousness Traumatic Brain Injury With Persistent Cognitive Deficits

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

ECOLOGIC_OR_COMMUNITY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MUSE Therapy Recipients With Chronic TBI

This cohort includes individuals aged 6 to 75 with chronic traumatic brain injury (TBI) who independently elect to receive MUSE (Multilineage-differentiating Stress-Enduring) stem cell therapy at licensed international treatment centers outside the United States. The study does not provide or administer the therapy; instead, it observes and documents real-world outcomes following treatment. Participants may receive MUSE cell infusions using varying doses, cell sources, and routes of administration, depending on the clinical site they choose. The study will collect longitudinal data on neurological function, quality of life, functional independence, and any adverse events over a 12-month follow-up period.

MUSE Stem Cell Therapy

Intervention Type BIOLOGICAL

MUSE (Multilineage-differentiating Stress-Enduring) stem cell therapy refers to the use of a naturally occurring subpopulation of mesenchymal lineage cells characterized by stress tolerance, expression of SSEA-3, and the capacity to differentiate into multiple cell types. Preclinical studies have shown that MUSE cells can migrate to sites of tissue injury, including the central nervous system, and may contribute to tissue repair through paracrine and regenerative mechanisms.

In this observational study, participants independently obtain MUSE stem cell therapy at licensed treatment facilities outside the United States as part of their personal medical care. The study team does not provide, administer, manufacture, or direct the therapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MUSE Stem Cell Therapy

MUSE (Multilineage-differentiating Stress-Enduring) stem cell therapy refers to the use of a naturally occurring subpopulation of mesenchymal lineage cells characterized by stress tolerance, expression of SSEA-3, and the capacity to differentiate into multiple cell types. Preclinical studies have shown that MUSE cells can migrate to sites of tissue injury, including the central nervous system, and may contribute to tissue repair through paracrine and regenerative mechanisms.

In this observational study, participants independently obtain MUSE stem cell therapy at licensed treatment facilities outside the United States as part of their personal medical care. The study team does not provide, administer, manufacture, or direct the therapy.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Individuals aged 6 to 75 years at the time of enrollment.

Documented history of traumatic brain injury (TBI) occurring at least 6 months prior to enrollment (chronic phase).

Participant has independently elected to receive MUSE (Multilineage-differentiating Stress-Enduring) stem cell therapy at a licensed treatment facility outside the United States.

Ability of the participant or legally authorized representative to provide informed consent for participation in an observational study.

Willingness to participate in remote or in-person follow-up assessments for up to 12 months.

Ability to provide medical records, laboratory reports, or treatment documentation when available.

Exclusion Criteria

Individuals who have not received, and do not plan to receive, MUSE cell therapy as part of their independent medical care.

Inability or unwillingness to complete study assessments (e.g., severe communication barriers not manageable through caregiver assistance or technology).

Any condition that, in the opinion of the study team, would make participation in an observational registry unsafe or infeasible (e.g., inability to provide minimal required data).

Planned participation in another research study that would prevent collection of observational outcomes for this registry.

Individuals currently incarcerated or in institutional settings where research participation is restricted.

\-

Minimum Eligible Age

6 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No